4E10 and 2F5 monoclonal antibodies: Binding specificities to phospholipids, tolerance, and clinical safety issues

AIDS

Volumn 22, Issue 5, 2008, Pages 649-651

  Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibodies to lipids; Antiphospholipid syndrome; Autoantibodies; Immunological tolerance; Neutralizing antibodies

Indexed keywords

CARDIOLIPIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; PHOSPHOLIPID;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BINDING SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LIPID BILAYER; LUPUS ERYTHEMATOSUS; NOTE; PRIORITY JOURNAL; VEIN THROMBOSIS; VIRION;

AIDS VACCINES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; PHOSPHOLIPIDS; PROTEIN BINDING;

EID: 43149113443     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f51922     Document Type: Note

References (21)

1. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005; 308:1906-1908.
2. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva JL. Membrane association and epitope recognition by HIV-1 neutralizing antigp41 2F5 and 4E10 antibodies. AIDS Res Hum Retroviruses 2006; 22:998-1006.
3. Alving CR, Beck Z, Karasavva N, Matyas GR, Rao M. HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies. Mol Membr Biol 2006; 23:453-465.
4. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies 2005; 14:59-67.
5. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 2007; 21:2131-2139.
6. Vcelar B, Stiegler G, Wolf HM, Muntean W, Leschnik B, Mehandru S, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS 2007; 21:2161-2170.
7. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol 2004; 25:174-179.
8. Cabiedes J, Cabral AR, Alarcón-Segovia D. Hidden anti-phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments. Eur J Immunol 1998; 28:2108-2114.
9. Kawaguchi S. Antiphospholipid antibodies reactive with bromelain-treated mouse erythrocytes in mice, rats and rabbits. Int Arch Allergy Appl Immunol 1991; 96:46-50.
10. Cabiedes J, Cabral AR, López-Mendoza AT, Cordero-Esperón HA, Huerta MT, Alarcón-Segovia D. Characterization of antiphosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J Autoimmun 2002; 18:181-190.
11. Alving CR. Antibodies to lipids and liposomes: immunology and safety. J Liposome Res 2006; 16:157-166.
12. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchère E, Coutinho A, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Meth 1998; 216:117-137.
13. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol 1986; 41:8-15.
14. Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2005; 106:4152-4158.
15. Rand J, Levin MB, Alving BM. The antiphospholipid syndrome: clinical presentation, diagnosis, and patient management. In: Kitchens C, Alving BM, Kessler C, editors. Consultative Hemostasis and Thrombosis, 2nd ed. Philadelphia, PA: Elsevier; 2007. pp. 319-338.
16. Fogler WE, Swartz GM, Alving CR. Antibodies to phospholipids and liposomes: binding of antibodies to cells. Biochim Biophys Acta 1987; 903:265-272.
17. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
18. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I: function in health and disease. Thromb Res 2004; 114:335-346.
19. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104:3598-3602.
20. Brown BK, Karasavvas N, Beck Z, Matyas GR, Birx DL, Polonis VR, et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 2007; 81:2087-2091.
21. Beck Z, Karasavvas N, Tong J, Matyas GR, Rao M, Alving CR. Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate. Biochem Biophys Res Commun 2007; 354:747-751.